Aurobindo Pharma arm API facility receives 3 observations from USFDA

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-12-13 07:28 GMT | Update On 2025-12-13 07:28 GMT

Hyderabad: Aurobindo Pharma has announced that the United States Food and Drug Administration (USFDA) concluded the inspection with three observations at the Unit-V, an API manufacturing facility, of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company, situated at Industrial Development Area, Chemical Zone, Pashamylaram Village, Patancheru Mandal, Sangareddy District, 502307, Telangana.

The inspection was held from December 01 to December 12, 2025.

"At the end of the current inspection, a ‘Form 483’ was issued with 03 observations which are procedural in nature, and we will respond to the USFDA within the stipulated timelines," the company stated in a BSE filing.

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

Read also: Aurobindo Pharma arm Eugia Pharma B.V incorporates wholly owned subsidiary in Chile

"The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe," Aurobindo added.

This development doesn’t have any impact on operations of the facility.

Read also: Aurobindo Pharma arm CuraTeQ Biologics incorporates new wholly owned subsidiary in Malta

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 31 manufacturing and packaging facilities that are approved by regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a R&D set-up.

Read also: Aurobindo Pharma China Plant incurring loss, break even expected by Q4

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Aurobindo Pharma arm API facility receives 3 observations from USFDA

Similar News

Dr Reddy's Labs gets 5 USFDA observations for Srikakulam facility

GSK Blujepa gets USFDA approval as oral option for uncomplicated urogenital gonorrhoea

Granules Life Sciences facility receives EIR from USFDA

Goa Invokes ESMA, Bans Pharma Strikes for 6 Months

Govt Sanctions Rs 181.59 Cr for Pharma Upgrades Under RPTUS, Parliament Informed

Himachal cracks down on pharma units, action taken against four facilities

Shilpa Medicare bags initial European authorization for Rotigotine Transdermal Patch for Parkinson's disease